Practice patterns for the evaluation and treatment of eosinophilic oesophagitis

Alimentary Pharmacology and Therapeutics - Tập 32 Số 11-12 - Trang 1373-1382 - 2010
A. F. Peery1,2, N. J. Shaheen1,2, E. S. Dellon1,2
1Center for Esophageal Diseases and Swallowing, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
2Center for Gastrointestinal Biology and Disease, Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA.

Tóm tắt

Aliment Pharmacol Ther 2010; 32: 1373–1382SummaryBackground  Although consensus guidelines for eosinophilic oesophagitis have been published, it remains unclear whether gastroenterologists follow these recommendations.Aim  To assess academic and community practice patterns for the evaluation and treatment of eosinophilic oesophagitis and to compare these practices with current guidelines.Methods  This was a prospective study of academic and community gastroenterologists using a self‐administered online survey.Results  A total of 60% (34 of 57) of academic and 29% (38 of 133) of community gastroenterologists completed the survey. Only 24% of academic and 3% of community gastroenterologists follow consensus guidelines to diagnose eosinophilic oesophagitis (P = 0.007). A proton pump inhibitor trial or negative pH study prior to diagnosis was required by just 25% of all gastroenterologists. A majority (60%) do not use the recommended threshold of 15 eosinophils per high powered field to diagnosis eosinophilic oesophagitis. Half (51%) mistakenly require a positive endoscopic finding. For first‐line treatment, about half of the gastroenterologists surveyed treat with a swallowed topical steroid (53% academic, 56% community; P = N.S.), consistent with the guidelines.Conclusions  There is variability in practice patterns for both diagnosis and treatment of eosinophilic oesophagitis. Ongoing education and research concerning diagnosis and treatment are needed.

Từ khóa


Tài liệu tham khảo

10.1053/j.gastro.2007.08.017

10.1056/NEJM200408263510924

10.1016/j.cgh.2009.06.023

10.1016/j.jaci.2004.11.006

10.1136/gut.2006.107714

10.1016/j.cgh.2009.08.030

10.1111/j.1365-2982.2009.01307.x

10.1111/j.1572-0241.2007.01396.x

10.1002/14651858.CD004065.pub3

10.1111/j.1572-0241.2007.01179.x

10.1038/ajg.2009.87

10.1007/s10620-009-0951-9

10.1007/BF01296781

10.1111/j.1442-2050.2009.01019.x

10.1053/j.gastro.2006.08.033

10.1016/j.cgh.2007.11.008

10.1053/j.gastro.2010.05.001

Straumann A, 2008, Budesonide as induction treatment for active eosinophilic esophagitis in adolescents and adults: a randomized, double‐blind, placebo‐controlled study (Bee‐I trial), Gastroenterology, 134, A104

10.1053/j.gastro.2010.07.048

Zhang X, 2010, In esophageal squamous epithelial cell lines from patients with eosinophilic esophagitis (EoE), omeprazole blocks the stimulated secretion of eotaxin‐3: a potential anti‐inflammatory effect of omeprazole in EoE that is independent of acid inhibition, Gastroenterology, 138

10.1007/s10620-009-0801-9

10.1038/ajg.2010.47

10.1111/j.1365-2036.2009.03935.x

10.1038/ajg.2010.101

Thông tin
Thông tin xuất bản

Alimentary Pharmacology and Therapeutics

Tập 32 Số 11-12

1373-1382

Thông tin tác giả